Ohio Businesses Remove THC Beverages Ahead of New Restrictions
THC beverage restrictions in Ohio are leading businesses to remove these products from shelves ahead of an impending ban. This regulatory change limits patient access to THC beverages outside licensed dispensaries. Clinicians should understand how these…
Product Recall: March 19, 2026 – Oklahoma Medical Cannabis Update
The Oklahoma medical cannabis product recall on March 19, 2026, impacts dispensaries statewide and introduces alternative patient identification methods. This update ensures patients maintain access to medical cannabis despite recall-related…
Impact of State Ban on THC Drinks and Cannabis Product Access
The state ban on THC drinks restricts access to certain cannabis products, impacting patients and specialty retailers. Clinicians must understand these regulatory changes to guide patients safely. This ban highlights the evolving legal landscape for…
Mississippi Bill Expanding Medical Cannabis Heads to Governor – NORML
Mississippi medical cannabis research authorization is expanding under new legislation. This change could increase clinical evidence for cannabis efficacy and safety. Clinicians should monitor how this impacts patient care and research oversight.
Ohio SB 56 Enforces Removal of Intoxicating THC from Unlicensed Retailers
Ohio cannabis enforcement SB 56 mandates removal of intoxicating THC products from unlicensed retailers. This reduces patient exposure to unregulated and potentially unsafe cannabis products. Clinicians should advise patients to use licensed cannabis…
Ohio Cannabis Referendum Will Not Appear on November Ballot
The Ohio cannabis referendum will not appear on the November ballot, keeping Senate Bill 56 restrictions in place. This affects medical cannabis access and clinician recommendations. Patients and providers face ongoing legal and access challenges in Ohio.
High Marijuana Taxes Don’t Effectively Deter Use, Study Shows
Recent research reveals cannabis tax increases patient use may not effectively reduce consumption. Higher taxes can drive patients toward unregulated markets, limiting clinical oversight. This challenges the use of taxation as a sole policy tool to deter…
Ohio’s Ban on Hemp-Derived Intoxicating Products and Its Clinical Impact
The hemp-derived intoxicating products ban Ohio marks a significant regulatory change affecting product availability. Clinicians must understand how this ban impacts patient access to lower-dose cannabis options. This shift directs patients toward…
Virginia Advances Cannabis Marketplace Regulation After Delays
Virginia cannabis marketplace regulation is advancing to establish a legal market after years of delay. This regulation enhances patient safety and product standards. Clinicians gain clearer guidance for patient counseling and safer cannabis use.
CED Digest: 230 Items — March 18, 2026
Cannabis compounds CBD and CBG fatty liver benefits are gaining attention for their potential to reduce hepatic steatosis. These cannabinoids show promise in improving metabolic health markers. Clinicians should consider emerging evidence on cannabis…